Clinical Trials Logo

BRAF Mutant Metastatic Melanoma clinical trials

View clinical trials related to BRAF Mutant Metastatic Melanoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT01512251 Completed - Clinical trials for BRAF Mutant Metastatic Melanoma

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

Start date: June 9, 2012
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2 clinical trial with the goal of determining whether the addition of the investigational agent BKM120 to vemurafenib will lead to improved 6-month progression-free survival in patients with BRAFV600E/K mutant melanoma.